Rallybio Corp
Close on Oct 19, 2026
- Market cap
- $94.80M
- P/E (TTM)
- 2.1
- Dividend yield
- –
About Rallybio
Pharmaceutical Preparations, SIC 2834
Rallybio Corporation is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapeutic candidates for individuals affected by severe and rare diseases. The company's pipeline centers on candidate treatments for complement dysregulation and hematological disorders. Its lead investigational asset is RLYB116, a complement component 5 inhibitor designed for subcutaneous administration to treat rare complement-mediated conditions. Rallybio is also developing RLYB332, a preclinical matriptase-2 antibody targeting diseases characterized by ineffective erythropoiesis and iron overload. The business further engages in research collaborations with industry partners to discover antibody-based therapies for rare metabolic and other disorders.
The company conducts clinical and preclinical research activities across various therapeutic development programs. Its intellectual property portfolio spans granted patents and pending patent applications across the United States, Europe, Japan, Canada, Australia, and numerous other international jurisdictions. The provided text does not identify the location of Rallybio's corporate headquarters.
Summary of the business section of Rallybio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Rallybio Corp
- Headquarters
- New Haven, CT
- Address
- 234 Church Street, Suite 1020 06510
- Phone
- (203) 859-3820
- Employees
- 14, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Hartford, Connecticut
Stock & identifiers
- Ticker
- RLYB
- Exchange
- Nasdaq
- IPO date
- Jul 30, 2021
- Shares outstanding
- 5M, Jul 30, 2026
- Public float
- $10.60M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-8 reverse, Mar 16, 2026; 1-for-8 reverse, Feb 6, 2026; 25-for-4, Nov 10, 2021
- SEC CIK
- 1739410
- CUSIP
- 75120L209
- ISIN
- US75120L2097
- LEI
- 254900OR8EZO4FXWJY12
- EIN
- 85-1083789
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stephen Uden | Chief Executive Officer, Director | 718,320 |
| Jonathan I. Lieber | Chief Financial Officer | 4,115 |
| Steven Ryder | Chief Medical Officer | 192,370 |
| Hui Liu | Director | 3,562 |
| Wendy Chung | Director | 3,562 |
| Helen M. Boudreau | Director | 6,542 |
| Ronald Hunt | Director | 2,301,603 |
| Martin Mackay | Director | 719,126 |
| Christine A. Nash | Director | – |
| Paula Soteropoulos | Director | 23,882 |
| Robert Lorne Hopfner | Director | 2,267,411 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 14 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 15, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 17, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Aug 29, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 8, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 25, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 30, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 29, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 7, 2021 | Name change | Name changed from Rallybio Holdings, LLC to Rallybio Corp |